Table 2.
Clinical characteristics of the validation study patients
| Validation set (n = 82 | |
|---|---|
| PFS (months) | |
| Median | 13.3 |
| OS (months) | |
| Median | 34 |
| Age (years) | |
| Median | 61.3 |
| Range | 40.4–79.3 |
| Stage (n) | |
| III | 73 |
| IV | 9 |
| Grade (n) | |
| 2 | 18 |
| 3 | 63 |
| Unknown | 1 |
| Chemotherapy (n) | |
| Adjuvant | 71 |
| Neo-adjuvant | 11 |
| Residual disease (n) | |
| No residual disease | 16 |
| ≤1 cm | 26 |
| > 1 cm and ≤2 cm | 5 |
| > 2 cm | 25 |
| Unknown | 10 |
| TP53 (n) | |
| Wild type | 6 |
| Mutant | 76 |
OS = overall survival; PFS = progression-free survival.